HYPOALBUMINEMIA EARLY IN TREATMENT HINDERS BENEFIT FROM IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH ADVANCED CANCERS.

被引：0
|
作者：
Guo, Y. [1 ]
Kulp, S. [1 ]
Mace, T. [2 ]
Coss, C. [1 ]
Phelps, M. [1 ]
Owen, D. [2 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
[2] James Canc Hosp, Columbus, OH USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2022年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PT-006
引用
收藏
页码：S63 / S64
页数：2
相关论文
共 50 条
  • [21] Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients
    Ma, Junxun
    Sun, Danyang
    Wang, Jinliang
    Han, Chun
    Qian, Yuanyu
    Chen, Guangying
    Li, Xiaoyan
    Zhang, Juan
    Cui, Pengfei
    Du, Wushuang
    Wu, Zhaozhen
    Chen, Shixue
    Zheng, Xuan
    Yue, Zhichao
    Song, Jia
    Gao, Chan
    Cai, Shangli
    Hu, Yi
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (03) : 365 - 372
  • [22] Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients
    Junxun Ma
    Danyang Sun
    Jinliang Wang
    Chun Han
    Yuanyu Qian
    Guangying Chen
    Xiaoyan Li
    Juan Zhang
    Pengfei Cui
    Wushuang Du
    Zhaozhen Wu
    Shixue Chen
    Xuan Zheng
    Zhichao Yue
    Jia Song
    Chan Gao
    Shangli Cai
    Yi Hu
    Cancer Immunology, Immunotherapy, 2020, 69 : 365 - 372
  • [23] Investigation of biomarkers for treatment of immune checkpoint blockade in progressive recurring head and neck cancers.
    Komatsu, Nobukazu
    Ono, Takeharu
    Yamada, Akira
    CANCER SCIENCE, 2021, 112 : 740 - 740
  • [24] Patients with Mesothelioma benefit from Checkpoint Inhibitors
    Krome, Susanne
    PNEUMOLOGIE, 2019, 73 (04):
  • [25] Checkpoint inhibitors in patients with advanced, refractory biliary tract cancers
    Liddell, S.
    Wintheiser, G.
    Jin, Z.
    Tran, N.
    Mahipal, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S192 - S192
  • [26] Characterizing "no treatment" decisions in patients with advanced-stage cancers.
    Akpoviroro, Ogheneyoma
    Akpoviroro, Oghenetejiro Princess
    Yossef, Kristena
    Castagne, Myriam
    Rodrigues, Elga
    Uwandu, Queeneth
    Bolden, Brian
    Mirza, Wasique
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 76 - 76
  • [27] Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors
    Yang, Kaili
    Li, Jiarui
    Zhao, Lin
    Sun, Zhao
    Bai, Chunmei
    FRONTIERS OF MEDICINE, 2022, 16 (05) : 773 - 783
  • [28] Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors
    Kaili Yang
    Jiarui Li
    Lin Zhao
    Zhao Sun
    Chunmei Bai
    Frontiers of Medicine, 2022, 16 (05) : 773 - 783
  • [29] Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors
    Kaili Yang
    Jiarui Li
    Lin Zhao
    Zhao Sun
    Chunmei Bai
    Frontiers of Medicine, 2022, 16 : 773 - 783
  • [30] Benefit of early-phase targeted, basket, and immune-based trials for patients with chemorefractory gastrointestinal (GI) cancers.
    Agarwal, Rajiv
    Cangemi, Nicholas Anthony
    Epstein, Andrew S.
    Harding, James J.
    Segal, Neil Howard
    Reidy, Diane Lauren
    Hyman, David Michael
    Saltz, Leonard B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345